EUVIMEDEUVIMED entdecken
Crossref

Eosinophilic granulomatosis with polyangiitis: A comprehensive narrative review

Slobodan Sajinovic, Vladimir Djurovic, Sonja Golubovic, Aleksandra Bukvic Sajinovic, Dejan Celic, Milica Popovic

Medicinski pregled · 2025 · 78 (9-12) · 270-277

DOI: 10.2298/mpns2512270s ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medicinski pregled, 2025. Verfasst von Slobodan Sajinovic und 5 weiteren Autor:innen. Die Arbeit nennt 50 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Eosinophilic granulomatosis with polyangiitis is a rare, systemic, immune-mediated vasculitis of small- to mediumsized blood vessels, characterised by eosinophil-rich inflammatory response, necrotising vasculitis, and granulomatous tissue reactions. Pathogenesis. The disease arises from a complex interplay of T helper 2- and T helper 1 cells mediated immunity, eosinophil activation, B-cell-autoantibody responses, and epithelialderived alarmins. Anti-neutrophil cytoplasmic antibodies positive (predominantly myeloperoxidase) patients exhibit a vasculitic phenotype, whereas anti-neutrophil cytoplasmic antibodies-negative patients show eosinophil-driven organ involvement. Key laboratory features include marked peripheral eosinophilia, elevated inflammatory markers, increased immunoglobulin E levels, and raised immunoglobulin G4 level. Clinical Presentation. The disease evolves through overlapping prodromal, eosinophilic, and vasculitic phases, producing variable organ involvement and a relapsing-remitting course. Heterogeneous presentation may obscure diagnosis and affect prognosis. Diagnosis and Differential Diagnosis. Diagnosis integrates clinical features, laboratory findings, and histopathologicy analysis. Differential diagnoses include other anti-neutrophil cytoplasmic antibody-associated vasculitides, hypereosinophilic syndromes, eosinophilic lung disorders, drug-induced reactions, parasitic infections, and immunoglobulin G4-related disease. Prognosis. Despite limited evidence, overall survival is generally favourable. Therapy. Management is guided by severity and prognostic factors. Glucocorticoids remain foundational, while biologics targeting interleukin-5, interleukin-4/ interleukin-13, anti-immunoglobulin E - as well as emerging approaches including B-cell depletion, alarmin inhibition, C5a receptor antagonism, and cellular therapies provide steroid-sparing options and improved disease control.

Conclusion

Despite favorable survival, morbidity persists due to disease relapses, organspecific complications, and long-term immunosuppression. Advances in immunogenetics, molecular profiling, and targeted therapies support a precision-medicine approach, multidisciplinary care and individualised management to optimise patient outcomes in eosinophilic granulomatosis with polyangiitis.

Zitieren

APA

Sajinovic, S., Djurovic, V., Golubovic, S., Sajinovic, A. B., Celic, D., & Popovic, M. (2025). Eosinophilic granulomatosis with polyangiitis: A comprehensive narrative review. Medicinski pregled, 78(9-12), 270-277. https://doi.org/10.2298/mpns2512270s

Vancouver

Sajinovic S, Djurovic V, Golubovic S, Sajinovic AB, Celic D, Popovic M. Eosinophilic granulomatosis with polyangiitis: A comprehensive narrative review. Medicinski pregled. 2025;78(9-12):270-277. doi:10.2298/mpns2512270s

BibTeX
@article{Sajinovic2025,
  author = {Sajinovic, Slobodan and Djurovic, Vladimir and Golubovic, Sonja and Sajinovic, Aleksandra Bukvic and Celic, Dejan and Popovic, Milica},
  title = {Eosinophilic granulomatosis with polyangiitis: A comprehensive narrative review},
  journal = {Medicinski pregled},
  year = {2025},
  volume = {78},
  number = {9-12},
  pages = {270--277},
  doi = {10.2298/mpns2512270s}
}
Kostenlos starten →